Managing Uncertainty in Benefit-Cost Analysis

Key Takeaways

• 36.7% of FY2023 non‑transfer rules lack cost/benefit numbers
• Qualitative welfare effects can skew regulatory outcomes
• Breakeven analysis offers a pragmatic alternative under uncertainty
• Courts reject vague cost estimates as insufficient justification
• Empirical studies can monetize habitat impacts via benefit‑transfer

Summary

Since the Reagan era, federal agencies have relied on benefit‑cost analysis to justify regulations, but a 2025 OMB report shows that over a third of major non‑transfer rules still lack quantified costs or benefits. Scholars argue this gap fuels both over‑ and under‑regulation, especially when qualitative welfare effects—such as habitat “stigma” under the Endangered Species Act—are left unmonetized. The article highlights alternative methods like breakeven analysis, which the FDA successfully used for food safety rules, and stresses courts’ intolerance for vague cost estimates. It calls for systematic quantification to restore analytical rigor.

Pulse Analysis

Benefit‑cost analysis has been the cornerstone of U.S. regulatory oversight for decades, yet its effectiveness hinges on the ability to translate disparate impacts into a common monetary metric. When agencies encounter uncertainty—whether due to data gaps, complex ecological interactions, or unpredictable market responses—they often resort to qualitative descriptions. This practice creates a transparency problem: stakeholders cannot gauge how such effects weigh against quantified costs, leading to potential regulatory bias and reduced public trust.

Recent case studies illustrate both the pitfalls and viable workarounds. The Endangered Species Act’s critical‑habitat designations generate "perceptional" effects on land values that are frequently labeled as unknown, despite a robust literature linking habitat status to property prices. Benefit‑transfer techniques, which adapt willingness‑to‑pay estimates from prior research, can fill these gaps without demanding costly primary studies. Conversely, the FDA’s 2015 food‑facility rule leveraged breakeven analysis, setting a clear threshold of illness reduction needed to justify compliance costs. By framing the decision in terms of a minimum benefit level, the agency sidestepped precise probability estimates while still providing a defensible economic rationale.

The legal landscape reinforces the need for rigorous quantification. Courts have repeatedly rejected agency excuses of “insufficient data,” insisting that regulators exercise expertise to produce the best possible economic estimates. Moving forward, agencies should institutionalize mixed‑method approaches—combining empirical monetization, benefit‑transfer, and breakeven thresholds—to ensure that all welfare effects receive comparable analytical treatment. Such reforms would enhance the predictive power of benefit‑cost analysis, reduce litigation risk, and promote more balanced regulatory outcomes.